Chemokine β-7 variants

Details Chemokine β-7 variants Chemokine β-7 variants

2006-02-21

2006-02-21

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

C530S324000, C435S069500, C435S069700, C435S071100, C435S071200, C435S254110, C435S254300, C435S320100, C435S471000

Reexamination Certificate

active

07001595

ABSTRACT:
The present invention relates to deletion and substitution mutant polypeptides of human chemokine β-7 (Ckβ-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ckβ-7, as well as deletion and substitution mutants, in medical treatment regimens. In particular, the Ckβ-7 polypeptides described herein may be employed to treat a variety of conditions, including rheumatoid arthritis, inflammation, respiratory diseases, allergy, and IgE-mediated allergic reactions.

REFERENCES:
patent: 4847325 (1989-07-01), Shadle et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5504003 (1996-04-01), Li et al.
patent: 5605817 (1997-02-01), Coleman et al.
patent: 5912327 (1999-06-01), Li et al.
patent: 6001606 (1999-12-01), Ruben et al.
patent: 6290948 (2001-09-01), White et al.
patent: 6406688 (2002-06-01), White et al.
patent: 6451562 (2002-09-01), Ruben et al.
patent: 6488925 (2002-12-01), Ruben et al.
patent: 6495128 (2002-12-01), Salcedo et al.
patent: 6623942 (2003-09-01), Ruben et al.
patent: 6632425 (2003-10-01), Li et al.
patent: 6811773 (2004-11-01), Gentz et al.
patent: 2002/0141972 (2002-10-01), White et al.
patent: 2002/0146390 (2002-10-01), White et al.
patent: 2002/0155094 (2002-10-01), White et al.
patent: 2003/0147846 (2003-08-01), Ruben et al.
patent: 2004/0024186 (2004-02-01), Li et al.
patent: 0 807 438 (1997-11-01), None
patent: WO-94/24285 (1994-10-01), None
patent: WO-95/17092 (1995-06-01), None
patent: WO-96/22374 (1996-07-01), None
patent: WO-96/34891 (1996-11-01), None
patent: WO-97/15594 (1997-05-01), None
patent: WO-97/29125 (1997-08-01), None
patent: WO-98/14582 (1998-04-01), None
Sherman et al. Bioassays vol. 3 No. 1, pp. 27-31, 1985.
Mikayama et al., “Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor,” Proc. Natl. Acad. Sci USA vol. 90, pp. 10056-10060, Nov. 1993.
Voet et al. John Wiley & Sons, Inc., pp. 126-128 and 228-234, 1990.
Adema, G.J., et al., “A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells,” Nature 387:713-717 (Jun. 1997).
Mieshima, K., et al., “A Novel Human CC Chemokine PARC That is Most Homologous to Macrophage-Inflammatory Protein-1α/LD78a and Chemotactc for T Lymphocytes, but Not for Monocytes,” J. Immunol. 159:1140-1149 (1997).
Millier, L., et al., GenBank Accession No. AA425047, (Oct. 1997).
Kodelia, V., et al., “Atternative Macrophage Activation-Associated CC-Chemokine-1, a Novel Structural Momologue of Macrophage Inflammatory Protein-1α with a Th2-Associated Expression Pattern,” J. Immunol. 160:1411-1418 (1998).
Schall, T.J., “Biology of the Rantes/Sis Cytokine Family,” Cytolone 3:165-189 (1991).
Weber, M., et al , “Deletion of the NH2-Terminal Residue Converts Monocyte Chemolacic Protein 1 from an Activator of Basophil Mediator Release to an Eosinophil Chemoattractant,” J. Exp. Med. 183:681-685 (1996).
Wells, T.N.C , and Peitsch, M.C., “The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and Expressed Sequence Tag Databases,” J. Leukocyte Biol. 61:546-550 (1997).
Arenzana-Seisdedos et al., “HIV blocked by chemokine antagonist,”Nature383:400 (Oct. 3, 1996).
Simmons et al., “Protein Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CR5 Antagonist,”Science 276:276-279 (Apr. 11, 1997).
Heath et al., “Chemokine Receptor Usage by Human Eosinophils,”J. Clin. Invest. 99(2):178-184 (Jan. 2, 1997).
Supplementary European Search Report, Application No. EP 99 96 0251, mailed Jun. 29, 2005.

Affiliated with

Also associated with

Rating

Chemokine β-7 variants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chemokine β-7 variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemokine β-7 variants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3710723